Respiratory pathogen panel testing compared to clinical diagnosis did not significantly change the proportion of 3-day ED revisits for upper respiratory complaints in children (6% vs 5%, P=0.57).
Cohort
Does respiratory pathogen panel testing reduce ED revisits within 3 days in children with acute upper respiratory illness?
Routine respiratory pathogen panel testing in the ED does not reduce short-term revisit rates for healthy children with uncomplicated upper respiratory infections.
Absolute Event Rate: 6% vs 5%
p-value: p=0.57
OBJECTIVE: Acute respiratory tract infections are the main cause of morbidity and emergency department visits for children. Recent advances in testing have brought about the ability to quickly diagnose many of the pathogens contributing to viral respiratory illness. The purpose of the study is to evaluate respiratory pathogen panel testing versus clinical diagnosis on the proportion of emergency department (ED) same-site revisits in an uncomplicated, healthy pediatric population. METHODS: This was an IRB-approved, retrospective cohort study. Patients discharged from the ED between the ages of 6 months to 3 years with a discharge diagnosis of acute upper respiratory infection from January 1, 2015, to May 31, 2023, were screened for inclusion. The primary outcome was the proportion of ED revisits within 3 days for upper respiratory illness-related complaints. RESULTS: There was no difference in ED revisits with 6% of patients in the RPP group versus 5% of patients in the No-RPP group returning in 3 days for upper respiratory complaints ( P =0.57). Of the 16 patients with RPP returning to the ED, the most common organism identified was rhinovirus/enterovirus. There was no difference in ED disposition after revisit, with the majority of patients discharging to home. CONCLUSIONS: The results of this study demonstrated no difference in the proportion of return visits to the ED in overall healthy children presenting with uncomplicated acute respiratory illness. These results support the consensus that viral respiratory panel testing may be performed on a selective basis to drive care in the emergency department.
Carman et al. (Wed,) conducted a cohort in Acute upper respiratory infection. Respiratory pathogen panel testing vs. Clinical diagnosis (No-RPP) was evaluated on Proportion of ED revisits within 3 days for upper respiratory illness-related complaints (p=0.57). Respiratory pathogen panel testing compared to clinical diagnosis did not significantly change the proportion of 3-day ED revisits for upper respiratory complaints in children (6% vs 5%, P=0.57).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: